Unlabelled: Saliva plays an important role in esophageal acid clearance. Reduction in salivary function has been considered in the pathogenesis of reflux esophagitis. Cisapride, a prokinetic agent, has been reported effective for treating mild-to-moderate grade gastroesophageal reflux disease. Some studies have shown that cisapride increases saliva volume and acid-buffering capacity. The aim of this study was to evaluate the effect of cisapride on salivary gland function by means of dynamic salivary scintigraphy.
Methods: Fifty-five patients with endoscopic reflux esophagitis (Savary-Miller Grades I-II) were enrolled in this study. In Group 1 (n = 29), patients were evaluated during the fasting state, both before and after cisapride treatment (5 mg, 3 times/day, before meals, for 2 wk). In Group 2 (n = 26), patients were evaluated during the postprandial state, both before and after cisapride treatment. Uptake ratio (UR) and excretion ratio (ER) of the salivary gland in each group were compared using the paired Student's t-test.
Results: In Group 1, no significant differences were found in UR or ER after cisapride treatment. However, in Group 2, ER increased significantly after treatment (p < 0.01), but UR did not show any significant change.
Conclusion: Cisapride can increase the secretion function of salivary glands during the postprandial phase but not the fasting phase.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Efficacy and Safety of Dual Delayed-Release Formulation of Esomeprazole in Patients with Gastroesophageal Reflux Disease: A Multicenter, Prospective, Observational Study].
Korean J Gastroenterol
January 2025
Hanmi Pharmaceutical Co., Ltd., Seoul, Korea.
Background/aims: Gastroesophageal reflux disease (GERD) is a chronic and recurrent condition requiring constant dietary management and medication. This study evaluated the efficacy and safety of HIP1601, a dual delayed-release formulation of esomeprazole, in patients with GERD in a clinical setting.
Methods: This prospective, multicenter, observational study was conducted at 309 medical institutions in Korea between June 2021 and March 2023.
Dexlansoprazole acts as a disruptor of the aryl hydrocarbon receptor and ITE.
Food Chem Toxicol
January 2025
Department of Biochemical Science and Technology, National Chiayi University, Chiayi, 60004, Taiwan, ROC. Electronic address:
Dexlansoprazole, a proton pump inhibitor, is commonly used to treat gastro-oesophageal reflux disease and erosive esophagitis. The activated aryl hydrocarbon receptor (AhR) functions as a transcription factor by binding to the aryl hydrocarbon response element (AHRE) of its target genes, with cytochrome P450 (CYP) 1A1 being the most well-known target. In this study, we demonstrated that dexlansoprazole stimulates AhR activity, leading to increased CYP1A1 expression.
View Article and Find Full Text PDFGastroesophageal Reflux in Infants and Children: Diagnosis and Treatment.
Am Fam Physician
January 2025
Duke University School of Medicine, Durham, N.C.
Gastroesophageal reflux is a common physiologic event in infants in which gastric contents pass from the stomach into the esophagus. Gastroesophageal reflux may be asymptomatic or cause regurgitation or "spit up." This occurs daily in approximately 40% of infants.
View Article and Find Full Text PDFUpdated Review of Proximal Gastrectomy for Gastric Cancer or Cancer of the Gastroesophageal Junction.
J Gastric Cancer
January 2025
Department of Gastroenterological Surgery, Cancer Institute Hospital Ariake, Tokyo, Japan.
Proximal gastrectomy (PG) has reemerged as a viable surgical option for managing proximal gastric cancer and gastroesophageal junction cancer, particularly for early-stage tumors, offering potential advantages over total gastrectomy (TG). This review examines the evolution of PG, emphasizing surgical techniques and outcomes. Although PG was initially abandoned due to postoperative complications such as reflux esophagitis, advances in reconstruction methods, such as the double-flap technique and double-tract reconstruction, have significantly improved patient quality of life and reduced complications.
View Article and Find Full Text PDFDevelopment and current status of anti-reflux esophagogastrostomy after proximal gastrectomy: a literature review.
Langenbecks Arch Surg
January 2025
Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215008, China.
Background: The selection of an appropriate gastrointestinal (GI) reconstruction procedure after proximal gastrectomy (PG) has long been a challenge. Surgeons have had a long history of exploring anti-reflux gastroesophageal anastomosis. The aim of this article is to systematically summarize the anti-reflux principles of GI reconstructive procedures through a review of the previous literature and to provide a theoretical basis for clinicians to select or innovate procedures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!